10-Q: Syndax Pharmaceuticals Reports Strong Q3 Revenue Growth

Syndax Pharmaceuticals, Inc. reported significant revenue growth in Q3 2025 driven by its newly commercialized products, Revuforj and Niktimvo, alongside a second FDA approval for Revuforj.

Summary

• Total revenues for the nine months ended September 30, 2025, increased to $103.6 million, up from $16.0 million in the comparable prior year period.
• Product revenue from Revuforj, net, was $32.0 million for the three months ended September 30, 2025, a 12% increase over Q2 2025, and $80.6 million for the nine months ended September 30, 2025.
• Collaboration revenue from Niktimvo, net, was $13.9 million for the three months ended September 30, 2025, a 27% increase over Q2 2025, and $23.0 million for the nine months ended September 30, 2025.
• Net loss for the nine months ended September 30, 2025, was $(217.4) million, an improvement from $(224.6) million in the prior year period.
• Revuforj received a second U.S. FDA approval on October 24, 2025, for the treatment of R/R AML with a susceptible NPM1 mutation.
• The company's cash, cash equivalents, and shortand long-term investments totaled $456.1 million as of September 30, 2025.
• Net cash used in operating activities increased to $(253.5) million for the nine months ended September 30, 2025, compared to $(217.5) million in the prior year period.

Sentiment

Score: 7

Explanation: The company demonstrates strong commercial progress with two approved products generating significant and growing revenues, and a second FDA approval for Revuforj. This indicates successful execution of its strategy. While still incurring substantial losses and cash burn, this is typical for a biopharma company in the commercialization phase. The robust pipeline and upcoming data presentations provide future growth potential, though the need for future capital raises and exposure to industry-specific and macroeconomic risks temper the sentiment.

Positives

• Significant increase in total revenues to $103.6 million for the nine months ended September 30, 2025, primarily driven by new product sales.
• Revuforj net revenue grew to $32.0 million in Q3 2025, a 12% increase over Q2 2025, with prescriptions increasing by 25%.
• Niktimvo net revenue reached $45.8 million in Q3 2025, a 27% increase over Q2 2025, with the company's collaboration revenue share at $13.9 million.
• Revuforj received a second FDA approval on October 24, 2025, for R/R AML with an NPM1 mutation, expanding its market.
• Revuforj was included in the NCCN Clinical Practice Guidelines in Oncology for AML as a Category 2A recommended treatment option.
• Multiple clinical trials for Revuforj and Axatilimab are ongoing, with data presentations scheduled for the 67th ASH Annual Meeting.
• Net loss decreased to $(217.4) million for the nine months ended September 30, 2025, compared to $(224.6) million in the same period last year, indicating an improvement in profitability metrics.

Negatives

• Total operating expenses increased to $314.2 million for the nine months ended September 30, 2025, up from $259.3 million in the prior year.
• Selling, general and administrative expenses significantly increased by $46.6 million for the nine months ended September 30, 2025, due to commercialization efforts.
• Cash, cash equivalents, and investments decreased from $692.4 million at December 31, 2024, to $456.1 million at September 30, 2025.
• Net cash used in operating activities increased to $(253.5) million for the nine months ended September 30, 2025, indicating higher cash burn.
• Accumulated deficit increased to $(1.4) billion as of September 30, 2025.
• Milestone and license revenue decreased to $0 for the nine months ended September 30, 2025, from $16.0 million in the prior year period.

Risks

• Undesirable side effects or other properties of products could delay or prevent regulatory approval, limit commercial scope, or result in negative consequences post-approval (e.g., Revuforj's boxed warning for differentiation syndrome, QTc prolongation, Torsades de Pointes).
• Significant competition from other biotechnology and pharmaceutical companies, including existing therapies for cGVHD (ibrutinib, belomosidil, ruxolitinib) and other agents in development for AML/ALL.
• Off-label use or misuse of products could harm reputation or lead to costly product liability suits and regulatory enforcement actions.
• Disruptions at the FDA, SEC, and other government agencies due to funding shortages or shutdowns (e.g., ongoing government shutdown starting October 1, 2025) could hinder timely review and approval of submissions.
• Unfavorable interest rates and geopolitical unrest (e.g., Russia-Ukraine, Israel-Hamas conflicts) could result in economic uncertainty, capital market volatility, and increased operating costs due to inflation, supply chain constraints, and labor issues.
• The company's ability to obtain and maintain regulatory approval for product candidates and the timing or likelihood of regulatory filings and approvals for such candidates.
• The ability to maintain licenses with UCB Biopharma Sprl and Vitae Pharmaceuticals, LLC.

Future Outlook

The company believes its available cash, cash equivalents, short-term and long-term investments, combined with expected Revuforj gross contribution and Niktimvo collaboration revenue, are sufficient to fund existing and planned cash requirements. It plans to continue significant R&D spending, particularly on late-stage clinical development. Future capital needs are expected to be met through equity offerings, debt financings, and additional license/collaboration arrangements. Enrollment in the MAXPIRe trial for IPF is expected to complete by the end of 2025, with topline data anticipated in the second half of 2026. REVEAL trials for newly diagnosed acute leukemia patients are expected to initiate by the end of 2025. Data from the R/R metastatic microsatellite stable colorectal cancer trial is expected in Q1 2026.

Management Comments

• We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies.
• We currently have two commercially approved products, Revuforj (revumenib) and Niktimvo (axatilimab-csfr), and a robust slate of clinical development programs.
• We plan to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional therapeutics to expand our pipeline.
• We anticipate that we will likely continue to incur significant losses for at least the next couple years.
• We believe that the combination of our available cash, cash equivalents, short-term and long-term investments, as well as our expected Revuforj gross contribution and Niktimvo collaboration revenue, is sufficient to fund existing and planned cash requirements.

Industry Context

Syndax Pharmaceuticals operates in the highly competitive biopharmaceutical industry, specifically focusing on innovative cancer therapies and fibrotic diseases. The company's recent FDA approvals for Revuforj and Niktimvo position it as a commercial-stage entity, moving beyond pure R&D. The focus on acute leukemias (AML, ALL) and chronic graft-versus-host disease (cGVHD) addresses significant unmet medical needs. The ongoing clinical trials for additional indications and combination therapies, along with presentations at major medical conferences like ASH, indicate active engagement in the scientific and commercial landscape. The industry faces challenges from intense competition, regulatory hurdles, and the high costs associated with drug development and commercialization, which Syndax also acknowledges.

Comparison to Industry Standards

• NA

Legal Proceedings

• As of September 30, 2025, the company was not party to any material legal or arbitration proceedings.

Related Party Transactions

• Collaboration with Incyte Corporation for the worldwide development and commercialization of axatilimab, including co-commercialization and co-promotion in the United States with equal sharing of profits and losses.
• License agreement with Vitae Pharmaceuticals, Inc. (a subsidiary of AbbVie, Inc.) for Menin Assets, involving milestone payments and royalties.
• License agreement with UCB Biopharma Sprl for axatilimab, involving milestone payments and royalties.
• Purchase and Sale Agreement with Royalty Pharma Development Funding, LLC, where Royalty Pharma purchased rights to certain revenue streams from net sales of Niktimvo in the United States for an upfront fee and ongoing royalty payments.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings to fund operations and development.
• Patients and physicians benefit from new FDA-approved therapies (Revuforj, Niktimvo) for acute leukemias and cGVHD, with ongoing trials aiming to expand treatment options.
• Employees are impacted by increased headcount to support commercialization and ongoing clinical trials, reflected in higher personnel and stock-based compensation costs.
• Collaborators (Incyte, AbbVie, UCB) are involved in significant financial arrangements including revenue sharing, milestone payments, and royalties, impacting their respective financial positions.
• Creditors, particularly Royalty Pharma, have a financial interest in Niktimvo's sales performance due to the revenue participation right.

Next Steps

• Initiation of REVEAL trials (Phase 3) for newly diagnosed acute leukemia patients with NPM1m or KMT2A-rearranged AML by the end of 2025.
• Completion of enrollment in MAXPIRe (Phase 2) trial for IPF by the end of 2025.
• Presentation of data from 12 revumenib abstracts and 11 axatilimab abstracts at the 67th American Society of Hematology (ASH) Annual Meeting.
• Reporting of data from the revumenib trial in R/R metastatic microsatellite stable colorectal cancer at a medical conference in the first quarter of 2026.
• Anticipated topline data from the MAXPIRe trial in the second half of 2026.
• Continued development of axatilimab in combination with standard of care therapies for newly diagnosed chronic GVHD patients (Phase 2 and pivotal Phase 3 trials).

Key Dates

Recommendation

Syndax Pharmaceuticals is demonstrating strong commercial execution with two newly approved products, Revuforj and Niktimvo, generating significant and growing revenues. The recent second FDA approval for Revuforj is a substantial positive catalyst, expanding its market potential. The company also maintains a robust clinical pipeline with multiple ongoing trials and upcoming data readouts, which could drive future value. However, the company continues to incur significant operating losses and cash burn, leading to a decrease in its cash and investment reserves. While management believes current liquidity is sufficient, the explicit mention of potential future equity or debt financings and the available ATM program indicate an ongoing need for capital. Given the strong commercial momentum and pipeline progress balanced against the continued cash consumption and the need for future financing, a 'hold' recommendation is appropriate for investors to monitor the trajectory of revenue growth, expense management, and pipeline advancements.

Keywords

Syndax Pharmaceuticals, Revuforj, revumenib, Niktimvo, axatilimab-csfr, AML, NPM1 mutation, KMT2A translocation, cGVHD, chronic graft-versus-host disease, biopharmaceutical, cancer therapies, FDA approval, clinical trials, menin inhibitor, CSF-1R blocking antibody, oncology, hematology, IPF, idiopathic pulmonary fibrosis